Abstracts Archive - Page 227 of 2425 - ACR Meeting Abstracts

Abstract Number: 0498 • ACR Convergence 2023
Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Arad Dotan¹, Niv Ben-Shabbat¹, Abdulla watad², Dennis McGonagle³ and Howard AMITAL², ¹Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Major adverse cardiovascular events (MACE) are known comorbidities and consequences of psoriasis (PsO) and psoriasis arthritis (PsA). Previous studies underlined the potential of immunomodulatory…
Abstract Number: 0455 • ACR Convergence 2023
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA
Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
Abstract Number: 0493 • ACR Convergence 2023
Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque
Rosa Arvizu-Rivera¹, Valeria Gonzalez-Gonzalez², Dionicio A. Galarza-Delgado³, Iris Colunga³, José Ramón Azpiri-López³, Victor Beltran⁴, Angel Arias Peralta⁵ and Jesus Alberto Cardenas-De la Garza⁶, ¹Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario UANL, Monterrey, Mexico, ⁴Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Approximately half of the patients with psoriatic arthritis (PsA) present with axial disease. Previously, it was reported that PsA-patients with axial involvement present a…
Abstract Number: 0499 • ACR Convergence 2023
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Alexis R Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Silky Beaty⁴, Robert Low⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Duluth, GA, ³CorEvitas, LLC, Waltham, MA, ⁴UCB Pharma, Smyrna, GA, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Improvement in both joint and skin manifestations is an important goal in the treatment of psoriatic arthritis (PsA). This study describes durability of 50%…
Abstract Number: 0508 • ACR Convergence 2023
Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA
Philip J. Mease¹, Lihi Eder², Alexis R Ogdie³, Atul Deodhar⁴, Subhashis Banerjee⁵, Miroslawa Nowak⁵, Jiyoon Choi⁶, Thomas Lehman⁷ and Vibeke Strand⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Lawrenceville, NJ, ⁷Bristol Myers Squibb, Philadelphia, PA, ⁸Stanford University, Palo Alto, CA
Background/Purpose: Pain is commonly cited by patients with PsA as affecting their daily activities and quality of life and may differ by sex1. In addition…
Abstract Number: 0456 • ACR Convergence 2023
The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course
Jason Tang¹, Dana Weisenfeld², Kumar Dahal², Linshanshan Wang³, Clara-Lea Bonzel³, Yumeko Kawano², Gregory McDermott², Tianxi Cai⁴ and Katherine Liao², ¹Harvard College, Belmont, MA, ²Brigham and Women's Hospital, Boston, MA, ³CELEHS Lab, Cambridge, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Strong clinical predictors for response to biologic and targeted synthetic disease modifying rheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) have yet to be identified.…
Abstract Number: 0502 • ACR Convergence 2023
Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients
Paras Karmacharya¹, Avery Fortier¹, Georgina Sellyn¹, Alexis R Ogdie² and Leslie Crofford³, ¹Vanderbilt University, Nashville, TN, ²University of Pennsylvania, Philadelphia, PA, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive inflammatory disease of the skin and musculoskeletal system, affecting over half a million US adults. With relatively…
Abstract Number: 0505 • ACR Convergence 2023
Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
Shashank Cheemalavagu¹, Yuxuan Jin² and M. Elaine Husni³, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Achieving minimal disease activity (MDA) is an important treatment goal in psoriatic arthritis (PsA), as it leads to improved clinical outcomes and quality of…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease¹, Maxime Dougados², Maureen Dubreuil³, Marina Nighat Magrey⁴, Helena Marzo-Ortega⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, ³Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁴Case Western Reserve University, University Hospitals, Cleveland, OH, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
Abstract Number: 0514 • ACR Convergence 2023
Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study
Olivier FAKIH¹, Maxime Desmarets², Bérenger Martin², Clément Prati¹, Elisabeth Monnet², Daniel Wendling³ and frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²INSERM CIC-1431, Besançon, France, ³Besançon University Hospital, Besançon, France
Background/Purpose: An increasing number of targeted therapies are available for the treatment of SpA. However, some patients retain active disease despite several lines of treatment.…
Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Rashmi Dhital, Rebecca Baer and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…
Abstract Number: 0512 • ACR Convergence 2023
Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort
Elodie Portier¹, Sylvie chevret², Adeline Ruyssen-Witrand³, Anouk Walter-Petrich², Maxime Dougados⁴ and Anna Molto⁵, ¹Hôpital Cochin, Paris, France, ²Saint Louis Hospital, Paris, France, ³Toulouse University Hospital, Toulouse, France, ⁴Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ⁵HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France
Background/Purpose: Current recommendations for the management of patients with axial spondyloarthritis (axSpA) emphasize the need of individualized strategy in the therapeutic decision. Thus, many factors…
Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Marie Hornez¹, Anna Molto², Maxime Leroy³, beatrice banneville⁴, Rakiba Belkhir⁵, elodie chauvet⁶, Marion Couderc⁷, Emanuelle Dernis⁸, sandra Desouches⁹, Valerie Devauchelle¹⁰, Aline Frazier-Mironer¹¹, Laure Gossec¹², elisabeth Gervais¹³, Hubert Marotte¹⁴, Christophe Richez¹⁵, Jeremie SELLAM¹⁶, Raphaele Seror¹⁷, Véronique Le Guern¹⁸, Gaelle Guettrot-Imbert¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Rene-Marc Flipo²⁰ and Jean-Guillaume Letarouilly²¹, ¹University of Lille, Lille, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³CHU Lille - Department of Biostatistics, Lille, France, ⁴Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, ⁵Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁶CH Perpignan, Perpignan, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸CH Le Mans, Le Mans, France, ⁹Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁰UBO, Brest, France, ¹¹APHP Lariboisiere Hospital, Paris, France, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹³CHU Poitiers, Poitiers, France, ¹⁴CHU Saint-Etienne, Saint-Etienne, France, ¹⁵Université de Bordeaux, Bordeaux, France, ¹⁶Sorbonne Université APHP, Paris, France, ¹⁷University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁸APHP Hôpital Cochin, Paris, France, ¹⁹Inserm DR Paris 5, Paris, France, ²⁰La Lettre du Rhumatologue, Paris, France, ²¹CHU Lille, Lille, France
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
Abstract Number: 0516 • ACR Convergence 2023
Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
Casper Webers¹, Rabab Nezam El-Din¹, Marin Been¹, Harald Vonkeman² and Astrid van Tubergen¹, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ²Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
Background/Purpose: In the management of axial spondyloarthritis (axSpA), treatment intensification (TI) is recommended in patients with high disease activity (HDA). However, in practice, in most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].